Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san diego blog main
11
×
biotech
san diego top stories
boston blog main
clinical trials
new york blog main
boston top stories
national top stories
san francisco blog main
fda
new york top stories
startups
san diego
san francisco top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
ipo
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
allergan
biogen
boston
cancer
What
medicines
11
×
drug
new
diseases
ipo
therapeutics
developing
disease
fda
genetic
rare
ago
bio
company
covid
deal
dyne
muscle
roundup
sciences
treat
year
abide
acquisitions
activity
advance
aiming
akcea
alnylam
ambys
amgen
amyloidosis
announced
appointed
approval
approvals
approved
attr
available
bacteria
Language
unset
Current search:
medicines
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
5 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines